Valuation: AbbVie Inc.

Market Cap 505B 451B 416B 377B 706B 47,916B 718B 5,011B 1,984B 25,105B 1,894B 1,854B 79,149B P/E 2026 *
36.5x
P/E 2027 * 27.1x
Enterprise Value 567B 506B 467B 424B 792B 53,788B 806B 5,625B 2,227B 28,181B 2,126B 2,081B 88,848B EV / Sales 2026 *
8.38x
EV / Sales 2027 * 7.6x
Free-Float
95.71%
Yield 2026 *
2.41%
Yield 2027 * 2.52%
1 day+0.82%
1 week+1.26%
Current month+10.04%
1 month+10.28%
3 months+12.84%
6 months+47.09%
Current year+30.68%
1 week 29.6
Extreme 29.6
30.7
1 month 26.93
Extreme 26.93
30.7
Current year 20.13
Extreme 20.13
30.7
1 year 20.13
Extreme 20.13
30.7
3 years 13
Extreme 13
30.7
5 years 11.25
Extreme 11.25
30.7
10 years 10.75
Extreme 10.75
30.7
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%+1.26% - - 505B
-2.54%+1.31%+54.27%+117.14% 1,135B
-1.42%+3.23%+38.56%+74.05% 635B
+0.16%+0.08%+25.29%+96.64% 505B
-0.31%+3.09%+44.14%+64.55% 378B
-1.34%-0.47%+66.04%+40.18% 358B
-0.68%+2.65%+22.98%+49.15% 295B
-1.20%+3.04%+2.33%+21.60% 266B
-1.79%+1.57%+50.56%+61.40% 237B
-0.73%-0.10%+29.02%+99.06% 193B
Average -0.90%+1.60%+37.02%+69.31% 444.85B
Weighted average by Cap. -1.10%+1.63%+41.02%+80.33%

Financials

2026 *2027 *
Net sales 67.63B 60.4B 55.8B 50.56B 94.6B 6,421B 96.16B 671B 266B 3,364B 254B 248B 10,606B 73.59B 65.72B 60.71B 55.02B 103B 6,986B 105B 731B 289B 3,660B 276B 270B 11,540B
Net income 13.95B 12.45B 11.5B 10.43B 19.51B 1,324B 19.83B 138B 54.81B 694B 52.34B 51.22B 2,187B 18.97B 16.94B 15.65B 14.18B 26.53B 1,801B 26.97B 188B 74.55B 943B 71.19B 69.67B 2,974B
Net Debt 61.85B 55.23B 51.02B 46.24B 86.51B 5,871B 87.94B 614B 243B 3,076B 232B 227B 9,698B 54.27B 48.46B 44.77B 40.57B 75.9B 5,152B 77.16B 539B 213B 2,699B 204B 199B 8,510B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-10-23 US$30.58 +0.82% 111
26-10-22 US$30.33 +2.12% 243
26-10-21 US$29.70 -2.40% 99
26-10-20 US$30.43 +1.26% 1,783
26-10-19 US$30.05 -0.50% 66
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
285.64USD
Average target price
284.79USD
Spread / Average Target
-0.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.